Dr. Lal PathLabs Limited

NSEI:LALPATHLAB 株式レポート

時価総額:₹231.4b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Dr. Lal PathLabs 過去の業績

過去 基準チェック /56

Dr. Lal PathLabsは、平均年間7.7%の収益成長を遂げていますが、 Healthcare業界の収益は、年間 成長しています。収益は、平均年間30% 13%収益成長率で 成長しています。 Dr. Lal PathLabsの自己資本利益率は19.2%であり、純利益率は16.1%です。

主要情報

7.7%

収益成長率

7.5%

EPS成長率

Healthcare 業界の成長29.4%
収益成長率13.0%
株主資本利益率19.2%
ネット・マージン16.1%
前回の決算情報31 Mar 2024

最近の業績更新

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

Recent updates

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01
What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04
Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28
Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Jul 07
Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 10
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Feb 13
Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dec 29
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

Sep 21
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 23
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Jun 11
Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

May 25
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Do Dr. Lal PathLabs's (NSE:LALPATHLAB) Earnings Warrant Your Attention?

Apr 28
Do Dr. Lal PathLabs's (NSE:LALPATHLAB) Earnings Warrant Your Attention?

Is Dr. Lal PathLabs (NSE:LALPATHLAB) A Risky Investment?

Feb 17
Is Dr. Lal PathLabs (NSE:LALPATHLAB) A Risky Investment?

収支内訳

Dr. Lal PathLabs の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NSEI:LALPATHLAB 収益、費用、利益 ( )INR Millions
日付収益収益G+A経費研究開発費
31 Mar 2422,2663,5774,1350
31 Dec 2321,7223,2983,8560
30 Sep 2321,2273,0133,7720
30 Jun 2320,5522,6382,8690
31 Mar 2320,1692,3883,5770
31 Dec 2220,1142,4353,3490
30 Sep 2220,1892,4803,2990
30 Jun 2219,8352,7133,2550
31 Mar 2220,8743,4483,4800
31 Dec 2120,3293,6693,3030
30 Sep 2119,8844,0413,2640
30 Jun 2119,2193,9443,1260
31 Mar 2115,8132,9162,5010
31 Dec 2014,5202,4072,3430
30 Sep 2013,2752,0032,1600
30 Jun 2012,6121,9552,0790
31 Mar 2013,3042,2592,2220
31 Dec 1913,2982,4052,5400
30 Sep 1912,9442,3222,4930
30 Jun 1912,4632,0862,4120
31 Mar 1912,0341,9922,3410
31 Dec 1811,6911,9232,2940
30 Sep 1811,3931,8252,2380
30 Jun 1810,9991,7612,1730
31 Mar 1810,5691,7072,1020
31 Dec 1710,1001,6178980
30 Sep 179,5481,5658080
30 Jun 179,3891,5867520
31 Mar 179,1241,5461,6940
31 Dec 168,9021,5767000
30 Sep 168,7131,8766760
30 Jun 168,2491,4136250
31 Mar 167,9131,3225800
31 Dec 157,6541,2012,15211
31 Mar 156,5969084970
31 Mar 145,5797631,75510

質の高い収益: LALPATHLABは 高品質の収益 を持っています。

利益率の向上: LALPATHLABの現在の純利益率 (16.1%)は、昨年(11.8%)よりも高くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: LALPATHLABの収益は過去 5 年間で年間7.7%増加しました。

成長の加速: LALPATHLABの過去 1 年間の収益成長率 ( 49.8% ) は、5 年間の平均 ( 年間7.7%を上回っています。

収益対業界: LALPATHLABの過去 1 年間の収益成長率 ( 49.8% ) はHealthcare業界25%を上回りました。


株主資本利益率

高いROE: LALPATHLABの 自己資本利益率 ( 19.2% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘